Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine

Inclusion Criteria:

- HIV-1 infected male or female subjects >= 18 years of age

- Screening plasma HIV-1 RNA >=1000 c/mL

- CD4+ cell count >=200 cells/millimeter (mm)^3

- ART-naive defined as having =<10 days of prior therapy with any antiretroviral agent
following a diagnosis of HIV-1 infection

- Female subjects of child bearing potential are eligible to enter if they are not
pregnant and willing to use protocol-specified methods of contraception to prevent
pregnancy during the study

Exclusion Criteria:

- Any evidence at screening of an active Centers for Disease and Prevention Control
(CDC) Category C disease

- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

- History of ongoing or clinically relevant hepatitis within the previous 6 months, and
subjects with moderate to severe hepatic impairment will be excluded

- Women who are breastfeeding

- Subject, who in the investigator's judgment, poses a significant suicide risk

- Any clinically significant finding on screening or baseline electrocardiograph (ECG)

- The presence of any specific laboratory abnormalities at Screening

- History of cardiac disease

- Clinically relevant pancreatitis

- Subjects who are unlikely to complete the dosing schedule due to a pre-existing
physical or mental condition

- Any condition which impairs the absorption, distribution, metabolism or excretion of
the investigational product

- Any evidence of primary resistance based upon the presence of a major resistance
associated mutation in the Screening HIV genotype, or any historical genotype

- Treatment with any protocol-specified excluded medication